Chagas Disease (CD), a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi,
accounts for the highest burden of parasitic diseases in the Western hemisphere. Current drug treatments for CD are
highly toxic and often ineffective, particularly for the chronic stage of the disease, a fact that clearly emphasizes the
importance of identification/validation of molecular targets for the development of new drugs to treat the disease. Here,
we review in details the evidences that suggest the existence of specific receptors for platelet-activating factor (PAF) in
T. cruzi, the role of PAF on the control of parasite differentiation and the potential of exploring these putative receptors as
new targets for the chemotherapy of CD.